CanPoland SA’s plans concerning its debut on the stock exchange

CanPoland SA’s plans concerning its debut on the stock exchange

CanPoland SA’s plans concerning its debut on the stock exchange 150 150 CanPoland SA

Łódź, May 11th, 2021

CanPoland SA’s plans concerning its debut on the stock exchange

The management board of the CanPoland SA, a leading Polish pharmaceutical company operating on the medical marijuana market, announced that it has begun the search for a brokerage house and consulting company that will support the CanPoland in the process of entering the stock exchange. The management board maintains its declarations about the  the company’s debut on the bourse in 2022.

Let us recall that CanPoland SA is launching a network of medical clinics specialising in cannabinoid therapy, has set up a subsidiary that will take care of laboratory testing of marijuana-derived materials and products and of launching cannabis cultivation for medical marijuana production, as soon as Polish legislation allows it, is entering the Lithuanian market by establishing its subsidiary there, is entering the Scandinavian market.

“For the last year, since the moment when the idea of going public came up, we started analysing the possibilities we had. We have already submitted inquiries to selected brokerage houses and consulting companies that could help us enter the main market of the Warsaw Stock Exchange. We already know that entering this market on the WSE is possible at the scheduled time”, said Zbigniew Pisarski, co-founder and chairman of the supervisory board of CanPoland SA.

About CanPoland SA

CanPoland SA is the first Polish-owned pharmaceutical company to trade internationally in medical marijuana. It’s also the first in Poland to build a production plant that is allowed to manufacture medical marijuana. The company is also active on the pharmaceutical repackaging services market and acts as the wholesaler of pharmaceuticals. In 2020, the company managed to acquire TT Pharma Sp. z o.o. (owned by the pharmaceutical giant Pelion SA) as its investor, now owning a 30 percent share in CanPoland SA. In order to implement the strategy of a vertical business organization (from cultivation to sale), together with the Canadian investor ICC (also active in the cannabis industry), CanPoland set up the The Health Company Poland. Its main area of activity is the production and distribution of raw materials, semi-finished products and a wide variety of final products from the “life science” range, based on active marijuana substances. The company’s offer is aimed at both the B2B market and the consumer market. The Health Company Poland works along the entire supply chain, from research and development plants and laboratories, through cultivation and modern technological and processing solutions, to direct sale of the highest quality cannabis products for business and the end consumer. The Health Company’s offer is available on the https://hempcloud.pl platform.

Contact for press:
Anna Posmyk, investor relations manager: a.posmyk@canpoland.com

Contact for investors:
Maciej Kociołek, M&A and strategy director: m.kociolek@canpoland.com

Ta strona używa plików cookie w celu usprawnienia i ułatwienia dostępu do serwisu oraz prowadzenia danych statystycznych. Dalsze korzystanie z tej witryny oznacza akceptację tego stanu rzeczy.
Polityka Cookies